Abogen Biosciences Showcases RNA Technology Platform and Clinical Pipeline at VWSEA 2025 & RNA Therapeutics & Manufacturing Asia 2025

Oct 31, 2025 16:30 CST Updated 16:30

Abogen

Nucleic Acid Drug Developer

Dr. Ying Bo, Founder, Chairman and CEO of Abogen, was invited to attend the event held in Bangkok, Thailand from November 5th to 6th.The 7th Asian Vaccine Conference (Southeast Asia) 2025AndThe 7th Vaccine World Asia Congress 2025 – South East Asia & RNA Therapeutics & Manufacturing Asia 2025。

Vaccine World Asia Congress (VWSEA) It is one of the most influential high-level dialogue platforms in the Asia-Pacific region for vaccine research and development and public health strategy, focusing on hot topics such as regional infectious disease prevention and control, new vaccine technology transformation, regulatory science, and industrialization implementation, and is regarded as a weathervane for vaccine policy formulation and industry cooperation in Southeast Asia.

RNA Therapeutics & Manufacturing AsiaFocusing comprehensively on the R&D, production, and commercialization of the entire RNA therapy industry chain, it has become one of the key and highly specialized platforms for building an innovative RNA drug ecosystem in the Asia-Pacific region. This conference will explore optimized pathways for RNA synthesis, purification, and quality control, and share new technologies for efficient, low-cost, large-scale manufacturing.

Two top-tier events were held concurrently in the same location, inviting60+The guest speaker attracted150+Participating Enterprises and400+Industry experts have provided a valuable platform for cross-disciplinary collaboration in vaccine development and RNA therapy innovation, which is expected to further consolidate Southeast Asia's leading position in the global vaccine and RNA innovation industry.

At the conference, Dr. Yingbo will join scientists and industry leaders from around the globe to discuss the innovative wave in the RNA industry and, as a speaker, share Abogen's achievements and latest clinical research progress in the RNA technology platform field.

Abogen Sharing Session

Special Discussion

Panel Discussion 01

Subject:Speed, Diversity, and Infrastructure: Delivering Clinical Trials in Southeast Asia

Time:November 5, 2025 13:30

Summary:

① Accelerate clinical processes through adaptive design and process simplification;

② Ensure participant diversity, reflecting the demographic characteristics of the Southeast Asian region;

③ Strengthen cross-border infrastructure construction and collaboration mechanisms to enhance clinical execution;

④ Address regional regulatory challenges, enhance clinical efficiency and accessibility.

Special Discussion

Panel Discussion 02

Subject:C-Suite Think Tank: Unlocking the Next Wave of mRNA-Based Vaccines, Therapeutics & Platforms in Asia: Advancing mRNA Drugs Towards Clinical Reality

Time:November 5, 2025 16:25

Summary:

① What are the emerging opportunities, key targets, and application directions for mRNA technology in Asia that are expected to achieve clinical breakthroughs?

② How can companies effectively balance pipeline layout and strategic management while maintaining scientific innovation?

③ How should Asian mRNA innovation companies reduce risks, extend cash flow cycles, and enhance investment attractiveness?

④ What lessons can be drawn from the rapidly evolving mRNA industry landscape in Asia to drive continuous growth in this field and enhance global influence?

Keynote Speech

Subject:Applications of mRNA Delivery Technology in Vaccines, Cancer, and Autoimmune Disease Treatment (Delivery of mRNA for Vaccines, Cancer and Autoimmune Diseases)

Time:November 6, 2025 11:15

Summary:

① Introduction to Abogen's RNA Technology Platform;

② Next-generation LNP delivery system: Achieving safe and efficient mRNA delivery in mice and non-human primates;

③ Latest Clinical Research Progress of Abogen in Vaccines, Oncology, and Autoimmune Diseases.

The joint hosting of these two conferences not only provided a high-level dialogue platform for scientists, industry players, and investors but also marked the deep integration of two cutting-edge fields—vaccines and RNA therapeutics—in the Southeast Asian region. Abogen's in-depth participation in the conference further highlights the increasingly important role of China's innovative biopharmaceutical companies in the global RNA ecosystem.

For more information, please visit the official website:

https://info.imapac.com/brochure/vwsea2025/